-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LllKZui63Cx4MbZQDJCFClcxQeHjF6shWxNSwUPPXDjWWUKJ9xXZJppHP27Y3x2x a8bJVDWwXKilPnzGxryTgQ== 0001036050-98-001739.txt : 19981022 0001036050-98-001739.hdr.sgml : 19981022 ACCESSION NUMBER: 0001036050-98-001739 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19981014 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19981021 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: INNOVIR LABORATORIES INC CENTRAL INDEX KEY: 0000901099 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133536290 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-21972 FILM NUMBER: 98728352 BUSINESS ADDRESS: STREET 1: 510 E 73RD ST CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2122494703 8-K 1 FORM 8-K FOR INNOVIR LABORATORIES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ---------------------------- FORM 8-K ---------------------------- CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 14, 1998 ---------------- INNOVIR LABORATORIES, INC. ------------------------------ (Exact name of registrant as specified in its charter)
Delaware 0-21972 13-3536290 - ------------------------------ ----------- ------------------ (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)
510 East 73rd Street, New York, NY 10021 - ---------------------------------- ---------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (212) 249-4703 -------------------- Not Applicable -------------------------------------------------------------- (Former name or former address, if changed since last report) 1 ITEM 5. OTHER EVENTS. On October 14, 1998, Innovir Laboratories, Inc. issued the press release filed herewith as Exhibit 99. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (a) FINANCIAL STATEMENTS No financial statements are required to be filed as a part of this report. (b) PRO FORMA FINANCIAL INFORMATION No pro forma financial information is required to be filed as a part of this report. (c) EXHIBITS 99 Press release, dated October 14, 1998. All other Items of this report are inapplicable. 2 SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Innovir Laboratories, Inc. Date: October 20, 1998 By:/s/ Francis M. O'Connell ------------------------ Name: Francis M. O'Connell Title: Chief Financial Officer 3 EXHIBIT INDEX ------------- 99 Press release, dated October 14, 1998. 4 EX-99 2 PRESS RELEASE, DATED OCTOBER 14, 1998 EXHIBIT 99 ---------- FOR IMMEDIATE RELEASE - --------------------- Media Contact: Laura A. Mastrangelo VIMRX Pharmaceuticals 302-998-1734/Pager 800-916-8038 Investor Contact: Dian Griesel, Ph.D. The Investor Relations Group 212-664-8489 INNOVIR CLOSES NEW YORK OPERATIONS TO FURTHER REDUCE EXPENSES NEW YORK, NY, October 14, 1998 - Innovir Laboratories, Inc. announced today its decision to close its New York operations to further reduce operating expenses. Innovir will move its management and core technology assets to the headquarters of its majority owner, VIMRX Pharmaceuticals Inc., in Wilmington, Delaware. Innovir continues to seek partners, investors or purchasers for its oligozyme technology, including the lead EGS (External Guide Sequence) technology, the recently discovered FRS/GSFRS (Functional Ribozyme Selection) technology, and related research programs. Oligozyme technology uses catalytically interactive oligomers, which are chemically modified RNA molecules that can selectively destroy disease-causing RNA molecules. The target for Innovir's oligozyme technology is to assist pharmaceutical researchers with drug discovery target identification and validation. In May 1998, Innovir announced a strategic refocusing to conserve limited capital resources. Since that strategic refocusing, Innovir has begun the process of closing its two European operations in Gottingen, Germany, and Cambridge, England. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the development of competing therapies and/or technologies, the terms of any future strategic alliances or dispositions of technology, the need for additional capital, and any additional factors described from time to time in the Company's periodic reports on Form 10-K and 10-Q, and any prospectus describing the Company's securities. # # # NOTE TO INVESTORS AND EDITORS: VIMRX's press releases are available on the Internet through www.vimrx.com and through BusinessWire's web site at http://www.businesswire.com. The releases are also available at no charge through BusinessWire's fax-on-demand service at 800-411-8792. 1 -----END PRIVACY-ENHANCED MESSAGE-----